Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Opthea Ltd Major Shareholding Notification 2010

Mar 25, 2010

32698_rns_2010-03-25_64296675-b65f-4f43-9bbe-1b2ee68b60e5.pdf

Major Shareholding Notification

Open in viewer

Opens in your device viewer

==> picture [133 x 41] intentionally omitted <==

26 March 2010

The Companies Section The Australian Stock Exchange Limited 530 Collins Street MELBOURNE VIC 3000

Dear Sir/Madam

Substantial Holding Notice for Antisense Therapeutics Limited

We enclose Form 604 “Notice of Change of Interests of Substantial Holder” with respect to holdings in Antisense Therapeutics Limited by Polychip Pharmaceuticals Pty Ltd (Polychip) (a wholly owned subsidiary of Circadian Technologies Limited) and Syngene Limited (an associate - 42.38% owned by Polychip).

Yours faithfully

Natalie Korchev Company Secretary

Level 1, 10 Wallace Avenue, Toorak, Victoria 3142, Australia P: +61 (3) 9826 0399 Circadian Technologies Limited F: +61 (3) 9824 0083 ABN 32 006 340 567 www.circadian.com.au

FORM 604

Corporations Act 2001 Section 671B

NOTICE OF CHANGE OF INTERESTS OF SUBSTANTIAL HOLDER


To: ANTISENSE THERAPEUTICS LIMITED (ANP) ACN: 095 060 745

1. Details of substantial holder (1)

Name: POLYCHIP PHARMACEUTICALS PTY LTD (POLYCHIP) (A WHOLLY OWNED SUBSIDIARY OF CIRCADIAN TECHNOLOGIES LIMITED): AND SYNGENE LIMITED (SYNGENE) (42.38% OWNED BY POLYCHIP) ACN: 006 455 456 (POLYCHIP) 006 161 753 (SYNGENE)

There was a change in the interests of the substantial holder : Due to transactions by the holder on: 24/3/2010 The previous notice was given to the company on: 5/2/2010 The previous notice was dated: 5/2/2010

2. Previous and present voting power

The total number of votes attached to all the voting shares in the company or voting interests in the scheme that the substantial holder or an associate (2) had a relevant interest (3) in when last required, and when now required, to give a substantial holding notice to the company or scheme, are as follows:

Class of securities
(4)
Previous notice Previous notice Previous notice Present notice Present notice
Person’s votes Voting power (5) Person’s votes Voting power (5)
Ordinary:
Polychip
Syngene LimitedA
Total
106,906,497
35,259,412
142,165,909
18.14%
5.98%
24.12%
101,906,497
30,259,412
132,165,909
17.29%
5.13%
22.42%

A Polychip Pharmaceuticals Pty Ltd has a 42.38% interest in Syngene Limited and Syngene Limited owns 30,259,412 ordinary shares in Antisense Therapeutics Limited.

3. Changes in relevant interests

Particulars of each change in, or change in the nature of, a relevant interest of the substantial holder or an associate in voting securities of the company or scheme, since the substantial holder was last required to give a substantial holding notice to the company or scheme are as follows:

Date of
change
Person whose
relevant interest
changed
Nature of change (6) Consideration
given in
relation to
change (7)
Class and
number of
securities
affected
Person’s
votes
affected
(no. of
shares)
24/3/10 Polychip Sale of 5,000,000 ordinary
ANP shares by Polychip
which has decreased
Polychip’s interests in
ANP.
$153,000 5,000,000
ordinary
shares.
5,000,000
votes.
24/3/10 Syngene Sale of 5,000,000 ordinary
ANP shares by Syngene
which has decreased
Syngene’s interests in ANP.
$153,000 5,000,000
ordinary
shares.
5,000,000
votes.

4. Present relevant interests

Particulars of each relevant interest of the substantial holder in voting securities after the change are as follows:

Holder of relevant
interest
Registered holder
of securities
Person entitled to
be registered as
holder (8)
Nature of
relevant
interest (6)
Class and
number of
securities
Person’s
votes
Polychip
Pharmaceuticals
PtyLtd
Polychip
Pharmaceuticals Pty
Ltd
Polychip
Pharmaceuticals
PtyLtd
Beneficial
Owner
Ordinary
shares
101,906,497
101,906,497
Syngene Limited
(Polychip has a
42.38% interest in
Syngene)
Syngene Limited Syngene Limited Beneficial
Owner
Ordinary
shares
30,259,412
30,259,412

5. Changes in association

The persons who have become associates (2) of, ceased to be associates of, or have changed the nature of their association (9) with, the substantial holder in relation to voting interests in the company or scheme are as follows:

Name and ACN (if applicable) Nature of association
Not applicable

6. Addresses

The addresses of persons named in this form are as follows:

Name Address (Registered Office)
PolychipPharmaceuticalsPtyLtd Level 1,10 WallaceAvenue,Toorak, Victoria
Circadian TechnologiesLimited Level 1,10 WallaceAvenue,Toorak, Victoria
SyngeneLimited Level 1,10 WallaceAvenue,Toorak, Victoria

Signed by:

Natalie Korchev Company Secretary 26 March 2010